GT
DFTX

Glenmede Trust’s Definium Therapeutics DFTX Stock Holding History

Glenmede Trust’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$543K Buy
+11,548
New +$285K ﹤0.01% 961
2022
Q3 		– Sell
-1,439
Closed -$13K – 1312
2022
Q2 		$13K Hold
1,439
– – ﹤0.01% 1247
2022
Q1 		$23K Buy
+1,439
New +$25K ﹤0.01% 1265

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Glenmede Trust's DFTX Position: Q2 2026 in Review

Glenmede Trust opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 11,548 shares worth $543K. The stake represents ﹤0.01% of the portfolio and ranks #961 among its holdings. This is a return to the name: Glenmede Trust previously reported a position in DFTX as recently as Q2 2022.

Glenmede Trust first reported a position in DFTX in Q1 2022 and has held it in 3 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Glenmede Trust held 11,548 shares of Definium Therapeutics worth $543K as of Q2 2026.
  • Definium Therapeutics was a new Glenmede Trust position in Q2 2026.
  • Definium Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #961 holding.
  • Glenmede Trust first reported a position in Definium Therapeutics in Q1 2022 and has held it in 3 quarters since.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.